Efficacy of ambroxol hydrochloride in the treatment of exacerbation of chronic obstructive pulmonary disease
10.3760/cma.j.issn.1008-6706.2019.17.002
- VernacularTitle: 盐酸氨溴索辅助治疗慢性阻塞性肺疾病加重期的效果观察
- Author:
Qijiong LI
1
Author Information
1. Department of Respiratory Medicine, Zhuji Central Hospital, Zhuji, Zhejiang 311800, China
- Publication Type:Journal Article
- Keywords:
Pulmonary disease, chronic obstructive;
Respiratory function tests;
Forced expiratory volume;
Blood gas monitoring, transcutaneous;
C-reactive protein;
Neutrophil infiltration;
Leukocytes;
Ambroxol
- From:
Chinese Journal of Primary Medicine and Pharmacy
2019;26(17):2053-2056
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the efficacy of ambroxol hydrochloride in the treatment of acute exacerbation of chronic obstructive pulmonary disease(COPD).
Methods:From January 2015 to December 2017, 84 patients with COPD exacerbation in Zhuji Central Hospital were selected and randomly divided into two groups according to the digital table, with 42 cases in each group.The control group was treated with routine therapy, the observation group was treated with ambroxol hydrochloride on the basis of routine treatment.The course of treatment in both two groups was 14 days.The clinical efficacy, clinical symptom disappearance time, pulmonary function index, inflammation index and adverse reaction were compared between the two groups.
Results:The total effective rate in the observation group was 95.24%(40/42), which was higher than that in the control group(78.57%, 33/42), and the difference was statistically significant(χ2=5.126, P<0.05). The disappearance time of cough, wheezing, sputum and dampness in the observation group was (4.01±0.68)d, (3.22±0.60)d, (3.62±1.25)d, (4.16±0.72)d, respectively, which were shorter than those in the control group [(5.32±1.17)d, (4.66±1.12)d, (4.50±1.83)d, (5.10±1.06)d](t=6.274, 7.345, 2.573, 4.754, all P<0.05). After treatment, the forced expiratory volume, oxygen partial pressure, carbon dioxide partial pressure, C-reactive protein, neutrophil count and total white blood cell count in the observation group were (0.99±0.32)L, (71.36±7.61)mmHg, (42.28±4.39)mmHg, (8.71±2.46)mg/L, (6.40±3.19)×109/L, (6.11±3.28)×109/L, respectively, which in the control group were (0.80±0.20)L, (65.28±7.29)mmHg, (48.40±6.00)mmHg, (13.60±4.50)mg/L, (11.45±5.27)×109/L, (7.81±3.82)×109/L, respectively, and the differences between the two groups were statistically significant(t=3.263, 3.739, 5.335, 6.179, 5.313, 2.188, all P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).
Conclusion:Ambroxol hydrochloride can shorten the time of disappearance of clinical symptoms, improve the clinical efficacy and improve the pulmonary function and inflammation related indicators in the exacerbation period of COPD.
